AACR 2020

Complete Coverage

High Mortality Rates in Patients With Thoracic Cancer and COVID-19

Patients with thoracic cancer and COVID-19 had a high mortality rate and were frequently not offered intensive care in the global TERAVOLT registry.

ctDNA Biomarker of Relapse After Resection in Early NSCLC

A ctDNA test identified patients who would develop early relapse after surgical resection of stage I to III NSCLC.

cfDNA Test May Detect Disease Among Patients Who Are Suspected of Having Cancer

A test using plasma cfDNA detected cancer in patients who were suspected to have cancer, and was able to predict tissue of origin among patients with confirmed cancer.

Multicancer Liquid Biopsy Test May Identify Cancer in Older Women

A multicancer liquid biopsy test identified multiple cancer types in older women with no history of cancer, according to a prospective study of nearly 10,000 women.

First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL

A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.

Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL

A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.

Racial and Ethnic Disparities Among Patients With Cancer and COVID-19

Racial and ethnic disparities have emerged among patients with cancer and COVID-19, with black and Hispanic populations experiencing disproportionality high mortality rates.

A Look at One Institution’s Approach To Cancer Care During the COVID-19 Pandemic

An institution in Italy has adapted their cancer care model to minimize the risk to patients and health care workers, while still prioritizing patients with cancer.

COVID-19 Not More Aggressive in French Cancer Patient Population

Patients with cancer did not demonstrate a more aggressive or lethal COVID-19 disease course in a French population.

Study Suggests Cancer Is Associated With Poor COVID-19 Outcomes

Patients with cancer who contracted COVID-19 demonstrated an aggressive presentation and poor outcomes, according to a retrospective study from Wuhan.

Rates of Treatment-Associated Pneumonitis Higher in Clinical Trials and Real-World Data

Pneumonitis occurred more frequently among patients with NSCLC and a prior history of noninfectious pneumonitis, and with immune checkpoint inhibitors compared with chemotherapy.

Atezolizumab Plus Enzalutamide Fails to Improve Outcomes in mCRPC

Atezolizumab plus enzalutamide failed to improve OS compared with enzalutamide alone among patients with mCRPC in the IMbassador250 trial.

Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma

Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.

Atezolizumab Plus BRAF/MEK Inhibition Prolonged PFS in Melanoma

Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.

Durvalumab Plus Olaparib and Chemotherapy Improved pCR in HER2-Negative Breast Cancer

The presenter said “there may be promising activity with olaparib and durvalumab in addition to paclitaxel” in this breast cancer subtype.